Antibodies

15 Feb 2022 Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
15 Feb 2022 Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
12 Feb 2022 Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
11 Feb 2022 Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
11 Feb 2022 Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
10 Feb 2022 IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19
10 Feb 2022 Akeso’s NGF monoclonal antibody (AK115) approved to initiate clinical trial in pain (including cancer pain)
10 Feb 2022 FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
09 Feb 2022 Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product
08 Feb 2022 Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
07 Feb 2022 Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy
07 Feb 2022 CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
05 Feb 2022 FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
04 Feb 2022 Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders
04 Feb 2022 ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
03 Feb 2022 Regio Biosciences Enters into License Agreement with AstraZeneca for Phase 2a Asset in Peripheral Artery Disease (PAD)
02 Feb 2022 Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)
01 Feb 2022 Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
01 Feb 2022 Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
01 Feb 2022 OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
01 Feb 2022 Akeso doses first patient in the phase III trial of ivonescimab combined with chemotherapy in EGFR-TKI resistant EGFR mutation advanced non-squamous non-small cell lung cancer
01 Feb 2022 NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone
01 Feb 2022 Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
01 Feb 2022 Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Bispecific Antibody Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
29 Jan 2022 FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top